Evidence map›Paper›PMID 32627326›Full record

ArticleAngewandte Chemie (International ed. in English)2020

Aptamers with Tunable Affinity Enable Single-Molecule Tracking and Localization of Membrane Receptors on Living Cancer Cells.

Pietro Delcanale, David Porciani, Silvia Pujals, Alexander Jurkevich, Andrian Chetrusca, Kwaku D Tawiah, Donald H Burke, Lorenzo Albertazzi

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06105177 (Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06105177 recruitingnot on this mapstarted 2023, after this paper: background citation

Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study

Typeobservational_patient_registrySponsorCatharina Ziekenhuis EindhovenRan2023 to 2026Enrolled800ConditionsLung Cancer
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. MultiplexedNucleic acid therapeutics · 2024
    Article
  10. Review
  11. Article
  12. Cell Surface Engineering Tools for Programming Living Assemblies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  13. Review
  14. Article
  15. Beyond DNA: new probes for PAINT super-resolution microscopy.Chemical communications (Cambridge, England) · 2023
    Review
  16. Review
  17. Small Fluorogenic Amino Acids for Peptide-Guided Background-Free Imaging.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  18. Small Fluorogenic Amino Acids for Peptide-Guided Background-Free Imaging.Angewandte Chemie (International ed. in English) · 2023
    Article
  19. In vitro selection of aptamers and their applications.Nature reviews. Methods primers · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Pietro DelcanaleInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 15-21, 08028, Barcelona, Spain.
David PorcianiDepartment of Molecular Microbiology & Immunology, School of Medicine, University of Missouri-Columbia, 1 Hospital Dr, Columbia, MO, 65212, USA.
Silvia PujalsInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 15-21, 08028, Barcelona, Spain.
Alexander JurkevichMolecular Cytology Core at MU Bond Life Sciences Center, University of Missouri-Columbia, USA.
Andrian ChetruscaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 15-21, 08028, Barcelona, Spain.
Kwaku D TawiahDepartment of Biochemistry, University of Missouri-Columbia, 117 Schweitzer Hall, Columbia, MO, 65211, USA.
Donald H BurkeDepartment of Molecular Microbiology & Immunology, School of Medicine, University of Missouri-Columbia, 1 Hospital Dr, Columbia, MO, 65212, USA.
Lorenzo AlbertazziInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 15-21, 08028, Barcelona, Spain.ORCID 0000-0002-6837-0812
Institute for Bioengineering of Catalonia · ESUniversity of Missouri · USUniversity of Missouri Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cell-surface markers are usually overexpressed or mutated protein receptors for which spatiotemporal regulation differs between and within cancers. Single-molecule fluorescence imaging can profile individual markers in different cellular contexts with molecular precision. However, standard single-molecule imaging methods based on overexpressed genetically encoded tags or cumbersome probes can significantly alter the native state of receptors. We introduce a live-cell points accumulation for imaging in nanoscale topography (PAINT) method that exploits aptamers as minimally invasive affinity probes. Localization and tracking of individual receptors are based on stochastic and transient binding between aptamers and their targets. We demonstrated single-molecule imaging of a model tumor marker (EGFR) on a panel of living cancer cells. Affinity to EGFR was finely tuned by rational engineering of aptamer sequences to define receptor motion and/or native receptor density.

Indexed as

Aptamers, NucleotideCell Line, TumorErbB ReceptorsHumansMicroscopy, FluorescenceReceptors, TransferrinSingle Molecule ImagingAptamers, NucleotideEGFR protein, humanErbB ReceptorsReceptors, Transferrinaptamerscell-surface receptorslive-cell imagingPAINTsingle-molecule tracking

Identifiers

PMID32627326
PMCPMC7590183
OpenAlexW3038422064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.